DeepMed Research

Concizumab

Generic Name: Concizumab

Drug Type: Biotech

CAS Number: 1312299-39-0

Unique Ingredient Identifier: 68603V9EAF

Background: Concizumab has been used in trials studying the treatment of Haemophilia A and Congenital Bleeding Disorder.

Clinical Trials

Post-marketing Surveillance (Special Use-results Surveillance) on Treatment With Alhemo

Not yet recruiting

Conditions: Haemophilia A, Haemophilia B

Interventions: Drug: Concizumab

First Posted Date: 2025-02-18

Last Posted Date: 2025-04-11

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 30

Registration Number: NCT06831734

Locations: 🇯🇵
Chiba university hospital_Pediatrics, Chiba, Japan
🇯🇵
St. Marianna University School of Medicine Hospital_Pediatrics, Kanagawa, Japan
🇯🇵
Nanbu Medical Center & Children's Medical Center, Okinawa, Japan

and more 2 locations

Post-Marketing Surveillance (All Case Surveillance) on Treatment With Alhemo® in Patients With Haemophilia A or Haemophilia B With Inhibitors

Conditions: Haemophilia B
Haemophilia A

Interventions: Drug: Concizumab

First Posted Date: 2024-02-29

Last Posted Date: 2025-04-11

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 23

Registration Number: NCT06285071

Locations: 🇯🇵
Kyushu university hospital_Pediatrics, Fukuoka, Japan
🇯🇵
Kagoshima City Hospital, Kagoshima, Japan
🇯🇵
St. Marianna University School of Medicine Hospital_Pediatrics, Kanagawa, Japan

and more 4 locations

A Research Study on How Well Concizumab Works for You if You Have Haemophilia A or B With or Without Inhibitors

Phase 3

Recruiting

Conditions: Haemophilia A and B With and Without Inhibitors

Interventions: Drug: Concizumab

First Posted Date: 2021-11-26

Last Posted Date: 2025-02-05

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 90

Registration Number: NCT05135559

Locations: 🇷🇴
Spitalul Clinic Judetean De Urgenta Bihor, Oradea, Romania
🇷🇺
Children Regional Clinical Hospital, Krasnodar, Russian Federation
🇷🇺
Morozovskaya municipal children hospital, Moscow, Russian Federation

and more 85 locations

Compassionate Use of Concizumab if You Have Haemophilia

Conditions: Congenital Haemophilia

First Posted Date: 2021-06-10

Last Posted Date: 2025-04-13

Lead Sponsor: Novo Nordisk A/S

Registration Number: NCT04921956

Locations: 🇺🇸
University of California San Francisco UCSF, San Francisco, California, United States
🇺🇸
Children's Hospital Los Angeles - Endocrinology, Los Angeles, California, United States
🇺🇸
Memorial Health University Medical Center, Savannah, Georgia, United States

and more 19 locations

Research Study to Look at How Well the Drug Concizumab Works in Your Body if You Have Haemophilia With Inhibitors

Phase 3

Active, not recruiting

Conditions: Haemophilia A With Inhibitors
Haemophilia B With Inhibitors

Interventions: Drug: Concizumab

First Posted Date: 2019-09-10

Last Posted Date: 2025-05-21

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 134

Registration Number: NCT04083781

Locations: 🇷🇸
University Clinical Centre Kragujevac, Kragujevac, Serbia
🇺🇸
Center for Inherited Blood Dis, Orange, California, United States
🇺🇸
Children's Healthcare Atlanta, Atlanta, Georgia, United States

and more 77 locations

Research Study to Look at How Well the Drug Concizumab Works in Your Body if You Have Haemophilia Without Inhibitors

Phase 3

Active, not recruiting

Conditions: Haemophilia B Without Inhibitors
Haemophilia A Without Inhibitors

Interventions: Drug: Concizumab

First Posted Date: 2019-09-09

Last Posted Date: 2025-05-21

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 158

Registration Number: NCT04082429

Locations: 🇷🇸
University Clinical Centre Kragujevac, Kragujevac, Serbia
🇷🇸
Clinical Centre of Vojvodina, Novi Sad, Serbia
🇷🇸
Institute for Mother and Child Health Care of Serbia, Belgrade, Serbia

and more 78 locations

A Trial Evaluating Efficacy and Safety of Prophylactic Administration of Concizumab in Patients With Severe Haemophilia A Without Inhibitors

Phase 2

Completed

Conditions: Haemostasis
Haemophilia A

Interventions: Drug: Concizumab
Drug: Turoctocog alfa

First Posted Date: 2017-06-22

Last Posted Date: 2021-11-16

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 36

Registration Number: NCT03196297

Locations: 🇬🇧
Novo Nordisk Investigational Site, London, United Kingdom

A Trial Evaluating the Efficacy and Safety of Prophylactic Administration of Concizumab in Haemophilia A and B Patients With Inhibitors

Phase 2

Completed

Conditions: Haemophilia B With Inhibitors
Congenital Bleeding Disorder
Haemophilia A With Inhibitors

Interventions: Drug: Concizumab
Drug: Eptacog alfa

First Posted Date: 2017-06-22

Last Posted Date: 2021-10-22

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 26

Registration Number: NCT03196284

Locations: 🇬🇧
Novo Nordisk Investigational Site, Sheffield, United Kingdom

Trial Investigating Safety, Pharmacokinetics and Pharmacodynamics of Concizumab Administered Subcutaneously to Haemophilia A Subjects

Phase 1

Completed

Conditions: Congenital Bleeding Disorder
Haemophilia A

Interventions: Drug: placebo
Drug: Concizumab

First Posted Date: 2015-07-07

Last Posted Date: 2017-07-21

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 24

Registration Number: NCT02490787

Locations: 🇬🇧
Novo Nordisk Investigational Site, Southampton, United Kingdom

Prev
1
Next

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy